Linklaters nets AstraZeneca role as conflict rules out Freshfields
Linklaters has scooped the lead advisory role on UK pharmaceutical giant AstraZeneca’s £702m offer for Cambridge Antibody Technology (CAT) after Freshfields Bruckhaus Deringer was conflicted out of the deal. AstraZeneca instructed Linklaters instead of regular counsel Freshfields because the latter firm acted for Abbott Laboratories in its dispute last year with CAT over the royalties […]